Media & Resources

IAVI was at the heart of global HIV/AIDS response dialogue during the 25th International AIDS Conference in Munich. With more than 40 oral abstract sessions, 50 invited-speaker sessions, 20 workshops, 30 symposia sessions, 100 satellite sessions, and 2,200 posters, AIDS 2024 showcased exciting community-led innovations alongside scientific breakthroughs and game changers.

Watch this video to learn more about VSV vaccines and how they work in the human body.VSV is the same platform technology IAVI and our collaborators are using to develop vaccines for hemorrhagic fever viruses such as Marburg, Lassa, and Ebola Sudan.

We envision a world where all people have equitable access to innovative vaccines and therapeutics. At IAVI, we believe that biomedical innovation should be a global public good. Together, we’re closing gaps from product design to delivery, reducing the risk that today’s outbreak will become tomorrow's pandemic. Because everyone deserves an equal opportunity for a healthy life.

Throughout 2022, IAVI continued to forge new and build on existing partnerships with governments, academia, industry, and other scientific consortia globally that advance vaccine and antibody candidates from concept to clinic. Our socio-behavioral research and global access initiatives support product development that is rooted in and informed by the realities of communities where disease burden is the greatest. Together with our network of clinical research center partners in Africa and India, we conducted clinical trials, strengthened in-country research capacity, and supported the training and education of the next generation of scientists and advocates. Read the full 2022 Annual Report here: bit.ly/IAVI_Annual_Report_2022

Watch this educational video to learn more about HIV bnAbs, sequential immunization, and IAVI's exciting new approach to HIV vaccine design. Broadly neutralizing antibodies, bnAbs for short, have the potential to neutralize or prevent infection with, many different HIV strains. IAVI’s goal is to design a series of sequential vaccine candidates that will prepare B cells to produce bnAbs before a person is exposed to HIV. These bnAbs could then protect the person from acquiring HIV if they were exposed to the virus in the future.  We are eager to continue our work developing a safe, effective HIV vaccine, which the world needs.

IAVI partnered with National AIDS and STI Control Program (NASCOP) in Kenya to produce a documentary film on mapping and size estimation of key populations of people living with HIV. This film provides useful information for stakeholders including communities of key populations, policymakers, civil society organizations, researchers, and funders specifically on who are the key populations, where they are in terms of hotspots and geographical areas, the size of these populations, and their numbers. Additionally, this documentary film provides a best practice for Africa on how other countries can innovatively conduct mapping and size estimation for and with key populations in Africa.

When you get a messenger RNA (mRNA) vaccine, your body receives the blueprint and all the instructions it needs to protect you. Watch this video to learn how mRNA vaccines are designed to teach our bodies to respond to a virus. Learn more at iavi.org.

Antibodies are natural proteins that the body makes that fight disease. Broadly neutralizing antibodies (bnAbs) are a special kind of antibody that is now being researched to see how they can play a role in HIV prevention. IAVI translates scientific discoveries into affordable, globally accessible public health solutions, and we believe all people should have access to innovative medicines.